Rating Change
Wells Fargo reiterated its Overweight rating on Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) on October 21, 2026.
reiterateNASDAQ:RAPP
Wells Fargo Reiterates Overweight Rating on Rapport Therapeutics, Inc. Common Stock (RAPP)
Wells Fargo reiterated its Overweight rating on Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) on October 21, 2026.
At publication ·
What changed
Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) · reiterate
- Firm
- Wells Fargo
- Rating
- Overweight to Overweight
- Price at event
- $25.06
- Market capitalization
- $1.1B
At a glance
Key takeaways
- Wells Fargo reiterated an Overweight rating on Rapport Therapeutics (RAPP) on October 21, 2026, with the stock trading at $25.06 and a market cap of $1.1 billion.
Market Context
Rapport Therapeutics, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $25.06 with a market capitalization of $1.1B.
Analyst coverage from Wells Fargo provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Rapport Therapeutics, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Rapport Therapeutics, Inc. Common Stock
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 21, 2026 | Jones Trading | Buy | N/A |
| Oct 21, 2026 | Guggenheim | Buy | N/A |
| Oct 21, 2026 | Wells Fargo | Overweight | N/A |
| Oct 20, 2026 | HC Wainwright & Co. | Buy | N/A |
| Oct 20, 2026 | BTIG | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View RAPP Stock Page
Frequently Asked Questions
What does the Overweight rating mean for RAPP?
A rating of Overweight from Wells Fargo reflects the analyst's outlook on Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RAPP forecast page.